Clinical Trial Update: Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating pembrolizumab (MK-3475) in combination with investigational agents for resectable non-small cell lung cancer is currently recruiting …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Investigational agents (unspecified)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Lung Neoplasm Malignant | Phase 2 | Status: RECRUITING